- $1.53bn
- $1.53bn
- $2.07m
Cyclerion rises on promising pre-clinical data for lead candidate
Brief: Cyclerion Therapeutics Announces Cy6463 Data Demonstrating Improved Cellular Energetics In Preclinical Models Of Mitochondrial Disease
Brief: Cyclerion Therapeutics Reports Positive Data For MELAS Treatment At Symposium
Brief: Cyclerion Co Received Deficiency Letter From Nasdaq
Brief: Cyclerion Announces Cy6463 Clinical Pipeline Progress And First Quarter 2022 Financial Results
Brief: Cyclerion Announces CY6463 Clinical Pipeline And Corporate Updates
Brief: Cyclerion Therapeutics And Ariana Pharma Announce An Artificial Intelligence-Driven Precision Medicine Collaboration
Cyclerion Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Cyclerion Therapeutics Announces Initiation Of Patient Dosing In CY6463 Phase 2A Study In Alzheimer's Disease With Vascular Pathology
Brief: Cyclerion Therapeutics Posts Quarterly Loss Of $11.3 Mln
Brief: Cyclerion Therapeutics Board Temporarily Appointed Peter Hecht As Interim CFO
Brief: Cyclerion Reports Publication of Preclinical Data showing Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Brief: Cyclerion Therapeutics - Net Loss Was Approximately $16.2 Mln For Q2 2021
Brief: Cyclerion Therapeutics Reports Q2 2021 Financial Results
Brief: Beacon Biosignals And Cyclerion Therapeutics Announce Strategic Partnership
Brief: Cyclerion Therapeutics And Beacon Biosignals Announce Expanded Strategic Partnership
Brief: Cyclerion Therapeutics Files For Sale Of 5.7 Mln Common Shares By Selling Stockholders
U.S. STOCKS ON THE MOVE-Target, Wendy's, Hyatt Hotels, Sage, crypto stocks
U.S. STOCKS ON THE MOVE-Gap, Wendy's, Fastly, Delta Air Lines, crypto stocks